



Urogenital Cancers: New Molecular and Translational Aspects on Carcinogenesis and Treatments

Guest Editors:

Dr. Silvia Di Agostino

IRCCS Regina Elena National
Cancer Institute, Roma, Italy

Dr. Vittoria Rago

Department of Pharmacy, Health
and Nutritional Sciences,
University of Calabria, Arcavacata
di Rende, 87036 Cosenza, Italy

Dr. Anna Perri

Department of Experimental and
Clinical Medicine, University
“Magna Graecia” Catanzaro,
88100 Catanzaro, Italy

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editors

We are pleased to invite you to submit a manuscript to the Special Issue “Urogenital Cancers: New Molecular and Translational Aspects on Carcinogenesis and Treatments”. Most types of urogenital cancer present with non-specific symptoms and the arrival of the diagnosis is often late.

Despite progress in the most innovative tumor therapies, the appearance of chemoresistance and metastasis represents a common cause of death in patients suffering from urological neoplasms. Therefore, it is necessary to develop new early diagnosis approaches and therapies that can improve treatment outcomes. For this purpose, it seems important to implement an understanding of the molecular mechanisms that occur in urological tumors and the research on molecular biomarkers capable of predicting tumor behavior and the risk of disease recurrence and chemoresistance.

The main aim of this Special Issue is to publish original research articles and reviews relating to urological neoplasms.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)